Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
As many as 10 family-owned or pharmacies faced closure each day around the United States of America in 2024. This isn’t due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback